Iovance Biotherapeutics Updates 2026 Revenue Guidance

What Happened
Iovance Biotherapeutics, Inc. (IOVA) announced on September 29, 2026 that it updated its full-year 2026 revenue guidance. The company issued a press release with the guidance update; that release is attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference.

Key Details

• Filing date: September 29, 2026 (Form 8-K, Item 8.01).
• Event: Press release issued updating full-year 2026 revenue guidance.
• Exhibit: Press release is included as Exhibit 99.1 to the 8-K.
• The 8-K does not include the numeric guidance in-line; investors should review Exhibit 99.1 for the specific figures.

Why It Matters
Updated revenue guidance is material information that can affect analyst models, investor expectations, and the company’s near-term valuation. Retail investors should read the attached press release (Exhibit 99.1) to see the actual revised revenue figures and compare them with prior guidance and analyst estimates before making investment decisions.